N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment

被引:10
|
作者
Shi, Yanlong [1 ]
Wang, Yizhu [1 ]
Zhang, Wenning [1 ]
Niu, Kaiyi [1 ]
Mao, Xinyu [1 ]
Feng, Kun [1 ]
Zhang, Yewei [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 2, Hepatopancreatobiliary Ctr, Nanjing, Jiangsu, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
N6-methyladenosine; hnRNPC; PD-L1; hepatocellular carcinoma; prognosis; immune infiltration; immunotherapy; RNA; M(6)A; TRANSCRIPTOME; ROLES;
D O I
10.3389/fendo.2023.1153802
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundIncreasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators and the immune microenvironment, providing a potential therapeutic target for patients with hepatocellular carcinoma (HCC). MethodsTotals of 371 HCC and 50 normal patients were included in this study. GSE121248 and GSE40367 datasets were used to validate the expression of HNRNPC. The R package "ConsensusClusterPlus" was performed to screen consensus clustering types based on the expression of m6A regulators in HCC. The R package "pheatmap", "immunedeconv", "survival", "survminer" and "RMS" were applied to investigate the expression, immunity, overall survival, and clinical application in different clusters and expression groups. Comprehensive analysis of HNRNPC in pan-cancer was conducted by TIMER2 database. Besides, HNRNPC mRNA and protein expression were verified by qRT-PCR and immunohistochemistry analysis. ResultsMost of m6A regulators were over-expressed excerpt for ZC3H13 in HCC. Three independent clusters were screened based on m6A regulators expression, and the cluster 2 had a favorable prognosis in HCC. Then, the cluster 2 was positively expression in macrophage, hematopoietic stem cell, endothelial cell, and stroma score, while negatively in T cell CD4(+) memory and mast cell. We identified HNRNPC was an independent prognostic factor in HCC, and nomogram performed superior application value for clinical decision making. Moreover, PD-L1 was significantly up-regulated in HCC tissues, cluster 1, and cluster 3, and we found PD-L1 expression was positively correlated with HNRNPC. Patients with HCC in high-expression groups was associated with tumor-promoting cells. Besides, HNRNPC was correlated with prognosis, TMB, and immune checkpoints in cancers. Particularly, the experiments confirmed that HNRNPC was positively expression in HCC cells and tissues. ConclusionThe m6A regulators play irreplaceable roles in prognosis and immune infiltration in HCC, and the relationship of HNRNPC and PD-L1 possesses a promising direction for therapeutic targets of immunotherapy response. Exploration of m6A regulators pattern could be build the prognostic stratification of individual patients and move toward to personalized treatment.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] N6-Methyladenosine (m6A) Reader IGF2BP1 Accelerates Gastric Cancer Development and Immune Escape by Targeting PD-L1
    Tang, Bingxi
    Bi, Lei
    Xu, Yanbin
    Cao, Lili
    Li, Xinli
    MOLECULAR BIOTECHNOLOGY, 2024, 66 (10) : 2850 - 2859
  • [22] Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma
    Qu, Nanfang
    Bo, Xiaotong
    Li, Bin
    Ma, Lei
    Wang, Feng
    Zheng, Qinghua
    Xiao, Xuhua
    Huang, Fengmei
    Shi, Yuanyuan
    Zhang, Xuemei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] N6-methyladenosine (m6A) Writer WTAP Potentiates Hepatocellular Carcinoma Immune Evasion and Aerobic Glycolysis
    Yu, Fatao
    Feng, Yuling
    Wang, Qing
    Sun, Jian
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2024, 82 (03) : 2321 - 2331
  • [24] N6-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis
    Zheng, Hao
    Cheng, Zhang-Jun
    Liang, Bo
    Wang, Zhen-Guang
    Tao, Yuan-Ping
    Huang, Sheng-Yu
    Ni, Jun-sheng
    Li, Hui-Fen
    Yang, Le
    Yuan, Sheng-Xian
    Wu, Jennifer
    Kawaguchi, Takumi
    Samant, Hrishikesh
    Zhou, Wei-Ping
    Xiang, Dai-Min
    Yang, Yuan
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (04): : 1009 - 1023
  • [25] Research Progress on Long Noncoding RNAs and N6-Methyladenosine in Hepatocellular Carcinoma
    Zhang, Wenjie
    Wu, Wenlong
    Meng, Qiang
    Yang, Long
    Yuan, Juzheng
    Tian, Zelin
    Ding, Rui
    Zhang, Xuan
    Wang, Jianlin
    Tao, Kaishan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology
    Lu, Jiahua
    Qian, Junjie
    Yin, Shengyong
    Zhou, Lin
    Zheng, Shusen
    Zhang, Wu
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma
    Li, Yu-jia
    Qiu, Yang-ling
    Li, Meng-ran
    Shen, Min
    Zhang, Feng
    Shao, Jiang-juan
    Xu, Xue-fen
    Zhang, Zi-li
    Zheng, Shi-zhong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (06) : 1130 - 1141
  • [28] The RNA modification N6-methyladenosine as a novel regulator of the immune system
    Shulman, Ziv
    Stern-Ginossar, Noam
    NATURE IMMUNOLOGY, 2020, 21 (05) : 501 - 512
  • [29] The RNA modification N6-methyladenosine as a novel regulator of the immune system
    Ziv Shulman
    Noam Stern-Ginossar
    Nature Immunology, 2020, 21 : 501 - 512
  • [30] PD-L1 expression in hepatocellular carcinoma
    Kanda, Hiroaki
    Mahmut, Yasin
    Shigematsu, Yasuyuki
    Sugiura, Yoshiya
    Yamamoto, Noriko
    Ishikawa, Yuichi
    CANCER SCIENCE, 2018, 109 : 1123 - 1123